Mutations that lead to increased activity of the Notch signalling pathway are well defined in human cancer. New work implicates decreased activity of this pathway in a type of blood cancer. See Letter p.230
References
Aster, J. C., Blacklow, S. C. & Pear, W. S. J. Pathol. 223, 263–274 (2011).
Klinakis, A. et al. Nature 473, 230–233 (2011).
Kopan, R. & IIagan, M. X. G. Cell 137, 216–233 (2009).
Koch, U. & Radtke, F. Curr. Top. Dev. Biol. 92, 411–455 (2010).
De Strooper, B., Vassar, R. & Golde, T. Nature Rev. Neurol. 6, 99–107 (2010).
Demehri, S. et al. PLoS Biol. 6, e123 (2008).
Dumortier, A. et al. PLoS One 5, e9258 (2010).
Duncan, A. W. et al. Nature Immunol. 6, 314–322 (2005).
Maillard, I. et al. Cell Stem Cell 2, 356–366 (2008).
Demehri, S., Turkoz, A. & Kopan, R. Cancer Cell 16, 55–66 (2009).
Liu, Z. et al. J. Clin. Invest. 121, 800–808 (2011).
Hanlon, L. et al. Cancer Res. 70, 4280–4286 (2010).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Kalaitzidis, D., Armstrong, S. The flipside of Notch. Nature 473, 159–160 (2011). https://doi.org/10.1038/473159a
Published:
Issue Date:
DOI: https://doi.org/10.1038/473159a
- Springer Nature Limited